Fig. 7.

Lysis of target cells by natural killer (NK) cells treated with N-803 or high-affinity NK cells (haNK) can be further increased with the addition of olaparib. a Lysis of BRCA wildtype prostate carcinoma (DU145) cells at 12 h and 36 h with or without pretreatment with olaparib (ola) and NK cells incubated in the presence or absence of an IL-15/IL-15Rα superagonist (N-803). b Lysis of DU145 at 36 h by haNK cells in the presence or absence of olaparib and avelumab (ave). p < 0.05*, p < 0.01**, p < 0.0001****